This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
WCET 2024
SUPS 2024
BCAN TT 2024
SNMMI 2024
ASCO 2024
AUA 2024
All Conferences
View All
PCF
UroToday Home
Recent Abstracts
Urologic Oncology
Prostate Cancer
Conferences
Recent Abstracts
AUA 2024: Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic Therapy (VTP) for Treatment of Low-Grade Upper Tract Urothelial Cancer (LG UTUC): Phase 3 Preliminary Results
May 4, 2024
AUA 2024: Computer Vision Analysis of Upper Tract Urothelial Carcinoma to Predict High vs Low Grade Pathology
May 4, 2024
AUA 2024: Development and Validation of Generalizable Interpretable AI Biomarkers to Predict Clinical Outcomes in BCG-Treated Patients with Non-Muscle Invasive Bladder Cancer
May 4, 2024
AUA 2024: Survival is Dramatically Improved for mRCC Patients with Sarcomatoid Features who are Treated with Cytoreductive Nephrectomy and Immune Checkpoint Inhibitors Regardless of Treatment Sequence
May 4, 2024
AUA 2024: Tumor Size Reduction (≥10% ) Resulting from Pre-Surgical Systemic Therapy Predicts Improved Survival Following Cytoreductive Nephrectomy
May 4, 2024
AUA 2024: Predicting Response to Intravesical BCG in High Risk Non-Muscle Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12 Center Cohort
May 4, 2024
AUA 2024: State-of-the-Art Lecture: Advances in Molecular Imaging for Renal Tumors
May 4, 2024
AUA 2024: Phase I Study of Intravesical Fc-Optimized Anti-CD40 Agonist Antibody 2141-V11 for Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
May 4, 2024
AUA 2024: Midlife Baseline PSA as a Predictor of Lethal Prostate Cancer: Racial Differences between Black and White Men
May 4, 2024
AUA 2024: Paradigm-Shifting Clinical Trials in Urology: SWOG S1011 - Subgroup Analysis of the Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Lymphadenectomy Performed at Time of Radical Cystectomy for MIBC
May 4, 2024
AUA 2024: Exploring the Dual Impact to Treatment Outcomes in Patients with Short Time to Nadir PSA Under Androgen Receptor Pathway Inhibitors for Metastatic Hormone-Sensitive Prostate Cancer
May 4, 2024
AUA 2024: Development of a Novel Risk Stratification for Prostate Cancer Patients Candidate to Radical Prostatectomy Staged with Preoperative PSMA-PET: The Key Role of Molecular Imaging
May 4, 2024
AUA 2024: Predicting Positive 68Ga-PSMA PET/CT Scans in Biochemical Recurrence Following Prostatectomy.
May 4, 2024
AUA 2024: Comparison of 68-Ga-PSMA PET/CT and Multiparametric MRI in Detecting Lymph Node Metastases in Patients with Intermediate or High-Risk Prostate Cancer
May 4, 2024
AUA 2024: Combination Regimen of Intravesical Docetaxel, Gemcitabine, and Cisplatin in Patients with BCG-unresponsive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
May 4, 2024
AUA 2024: Integrating MR and Ultrasound Images for AI-based Prostate Cancer Detection in Transrectal Ultrasound Images: A Comparative Assessment with Clinicians
May 4, 2024
AUA 2024: Characteristics of PI-RADS 5 Lesions with a Negative or Gleason Grade Group 1 Biopsy
May 4, 2024
AUA 2024: Enhancing Bone Health Screening for Prostate Cancer Patients Starting Androgen Deprivation Therapy: The Auto-Recruit Outpatient System
May 4, 2024
AUA 2024: Identifying The Optimal Candidate for Concomitant Androgen-Deprivation Therapy Among Patients Receiving Metastasis-Directed Therapy For Positive PSMA PET and Primary or Secondary Biochemical Recurrence from Prostate Cancer
May 4, 2024
AUA 2024: Correlation of Intraprostatic SUVmax During PSMA PET/CT and Adverse Pathology at Radical Prostatectomy
May 4, 2024
Page 17 of 576
Start
Prev
12
13
14
15
16
17
18
19
20
21
Next
End
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free